The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...

Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...

The U.S. is having its worst year for measles spread in more than three decades, with a total of 1,288 cases nationally and ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims.

Zepbound shows fewer side effects than Wegovy in obesity treatment study Research highlights Zepbounds advantages over Wegovy in treating obesity with less nausea.

Zepbound and Wegovy are prescribed to reduce and manage weight in certain adults. Learn about their other uses and how the drugs compare.

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.